Login to Your Account



Clinic Roundup


Tuesday, July 12, 2011
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., filed a clinical trial application with the Medicines and Healthcare products Regulatory Agency for a Phase I trial of ALN-PCS, an RNAi therapeutic for treating severe hypercholesteremia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription